Investors

OvaScience is a life sciences company focused on the discovery, development and commercialization of new treatments for infertility.

OVAS (Common Stock)
Price & Exchange
$35.37
NASDAQ
Change (%)
 Stock is Up 1.44 (4.24%)
Volume
1,260,945
06/01/15      4:15 p.m. ET

Minimum 20 minute delay
Refresh quote

Investor Overview

Webcast ImageWebcast
Ovascience Inc at Jefferies 2015 Global Healthcare Conference (Replay)
06/01/15 at 2:30 p.m. ET
Ovascience Inc at Jefferies 2015 Global Healthcare Conference
Monday, June 1, 2015 2:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Recent News

More »
DateTitle 
05/26/15OvaScience to Present at the Jefferies 2015 Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 26, 2015-- OvaScienceSM (NASDAQ:OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that Company management will present at the Jefferies 2015 Healthcare Conference on Monday, June 1, 2015 at 2:30 pm ET at the Grand Hyatt in New York City. A live audio webcast of the presentation can be accessed by visiting the Investo... 
Printer Friendly Version
05/18/15OvaScience Announces Ravi Mehrotra, Ph.D., Joins as Chief Corporate Development Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 18, 2015-- OvaScienceSM (NASDAQ:OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that Ravi Mehrotra, Ph.D., has joined the Company as Chief Corporate Development Officer. Dr. Mehrotra joins OvaScience from Credit Suisse LLC, where he served as Global Head of Biotechnology Equity Research. “Ravi brings a unique persp... 
Printer Friendly Version
05/15/15OvaScience’s AUGMENT Fertility Treatment Continues to Demonstrate Improved Pregnancy Rates in Women with Very Poor Prognoses
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 15, 2015-- OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today additional clinical experience with the Company’s AUGMENTSM fertility treatment, showing improved clinical pregnancy rates in women with poor prognoses, including poor egg health and embryo quality, who previously failed multiple cycles of in ... 
Printer Friendly Version
05/11/15OvaScience Reports First Quarter 2015 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 11, 2015-- OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today reported first quarter 2015 financial results and highlighted recent accomplishments. “We are confident in our ability to achieve our goals this year as demand for the AUGMENT treatment grows and we make progress toward bringing other new option... 
Printer Friendly Version

Upcoming Events

More »
DateTitle
06/04/15 9:00 a.m. ET
2015 Annual Meeting of Ovascience Stockholders
LocationAthenaeum Building 215 First Street Seminar Room, First Floor
Cambridge, MA 02142
Powered by Thomson Reuters
Data Provided by Thomson Reuters
Minimum 20 minutes delayed